Roche Gets UK Early Access OK For New Hemophilia Drug

The UK regulator is allowing patients to be treated with Roche’s as yet unlicensed hemophilia drug, emicizumab, under the country’s early access scheme. Hemlibra is already approved in the US and is in the final stages of review in the EU, where it is undergoing accelerated assessment.

RedBloodCellsOnWhite_1200x675
UK All Clear For Roche's Hemophilia Drug Emicizumab Under Early Access Scheme • Source: Shutterstock

The UK Medicines and Healthcare products Regulatory Agency is allowing Roche to make its promising new but as yet unlicensed hemophilia drug, Hemlibra (emicizumab), available to patients under the early access to medicines scheme (EAMS).

The UK's decision to allow patients early access to emicizumab comes as the drug is nearing the final stages of...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Product Reviews

EU Biosimilar Filings, Opinions And Approvals

 
• By 

<p>Executive Summary</p> <p>A list of EU biosimilar filings, CHMP opinions and EU marketing authorizations, including details of the biosimilar company, the brand name/INN, indication(s), the reference product/company, and the date and type of event.</p>

Stealth’s Elamipretide: Efficacy In Barth Syndrome Not Shown, US FDA Says

 
• By 

Cardiovascular and Renal Drugs Advisory Committee will consider whether open-label extension data from a randomized trial that failed its primary endpoint, along with a historical control comparison, are enough to support approval in the ultra-rare disease.

New EU Approvals

<p>Executive Summary<p> <p>The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add six new products, incl/ding Ixchiq, Valneva's chikungunya virus vaccine</p>

More from Pink Sheet

COVID Vaccines: US FDA Changes Course, Wants New Formulas To Target KP.2 Subvariant ‘If Feasible’

 
• By 

Revised recommendation is based on most recent data on circulating strains in US, where KP.3 is now dominant. Novavax sticks with plans targeting the JN.1 ‘parent strain.’

Nancy Tests New Podcast Template

 

Pink Sheet reporter and editors discuss the US FDA’s changes to the COVID-19 vaccine indication and its revocation of the vaccine emergency use authorizations, as well as new vaccine coverage and reimbursement questions.

PinkSheet-R&D-Free: ‘Ranking’ article that includes different Composer content

 
• By 

To make your document look professionally produced, Word provides header, footer, cover page, and text box designs that complement each other. For example, you can add a matching cover page, header, and sidebar. Click Insert and then choose the elements you want from the different galleries.